Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Anticoagulants | 72 | 2023 | 4600 | 3.980 |
Why?
|
Venous Thromboembolism | 26 | 2023 | 1671 | 3.060 |
Why?
|
Thrombophilia | 15 | 2023 | 305 | 3.050 |
Why?
|
Venous Thrombosis | 42 | 2020 | 1239 | 2.930 |
Why?
|
Factor VII | 25 | 2010 | 139 | 2.770 |
Why?
|
Factor VII Deficiency | 17 | 2006 | 32 | 2.350 |
Why?
|
Thromboembolism | 34 | 2022 | 987 | 2.180 |
Why?
|
Blood Coagulation | 46 | 2019 | 1127 | 2.100 |
Why?
|
Prothrombin | 40 | 2007 | 185 | 1.890 |
Why?
|
Polysaccharides | 23 | 2008 | 1059 | 1.690 |
Why?
|
Thrombosis | 33 | 2023 | 2968 | 1.650 |
Why?
|
Factor V | 17 | 2011 | 178 | 1.640 |
Why?
|
Fibrinolytic Agents | 19 | 2020 | 2158 | 1.540 |
Why?
|
Thrombin | 34 | 2013 | 598 | 1.530 |
Why?
|
Blood Coagulation Factors | 24 | 2022 | 355 | 1.290 |
Why?
|
Hemorrhage | 25 | 2022 | 3461 | 1.140 |
Why?
|
Hemostasis | 21 | 2023 | 458 | 1.070 |
Why?
|
Antithrombin III Deficiency | 12 | 2017 | 30 | 1.000 |
Why?
|
Enoxaparin | 17 | 2020 | 377 | 1.000 |
Why?
|
Factor VIIa | 15 | 2009 | 101 | 0.980 |
Why?
|
beta-Alanine | 2 | 2015 | 74 | 0.950 |
Why?
|
Hemophilia B | 9 | 2015 | 81 | 0.900 |
Why?
|
Heparin | 15 | 2019 | 1637 | 0.880 |
Why?
|
Antithrombins | 13 | 2013 | 304 | 0.820 |
Why?
|
Hemophilia A | 6 | 2023 | 351 | 0.810 |
Why?
|
Warfarin | 21 | 2013 | 1497 | 0.810 |
Why?
|
Pulmonary Embolism | 15 | 2020 | 2375 | 0.780 |
Why?
|
Pregnancy Complications, Hematologic | 5 | 2011 | 183 | 0.760 |
Why?
|
Heparin, Low-Molecular-Weight | 7 | 2020 | 339 | 0.740 |
Why?
|
Benzimidazoles | 3 | 2015 | 850 | 0.730 |
Why?
|
Antithrombin III | 20 | 2008 | 128 | 0.710 |
Why?
|
Point Mutation | 8 | 2006 | 1624 | 0.690 |
Why?
|
Thrombolytic Therapy | 7 | 2020 | 2162 | 0.690 |
Why?
|
Factor Xa | 15 | 2022 | 162 | 0.680 |
Why?
|
Orthopedic Procedures | 13 | 2004 | 1289 | 0.640 |
Why?
|
Intracranial Hemorrhage, Traumatic | 2 | 2017 | 54 | 0.630 |
Why?
|
Thromboplastin | 14 | 2012 | 291 | 0.630 |
Why?
|
Factor IX | 15 | 2009 | 77 | 0.610 |
Why?
|
Fibrin Fibrinogen Degradation Products | 8 | 2019 | 426 | 0.580 |
Why?
|
Aortic Rupture | 1 | 2019 | 312 | 0.550 |
Why?
|
Protein C | 15 | 1995 | 138 | 0.540 |
Why?
|
Arthroplasty, Replacement, Knee | 9 | 2020 | 1458 | 0.510 |
Why?
|
Biological Products | 1 | 2023 | 860 | 0.490 |
Why?
|
Craniocerebral Trauma | 1 | 2017 | 482 | 0.430 |
Why?
|
Administration, Oral | 13 | 2019 | 3914 | 0.420 |
Why?
|
Morpholines | 6 | 2013 | 571 | 0.400 |
Why?
|
Peptide Fragments | 27 | 2020 | 5096 | 0.400 |
Why?
|
Antidotes | 1 | 2012 | 138 | 0.390 |
Why?
|
Humans | 242 | 2023 | 744366 | 0.390 |
Why?
|
Diclofenac | 1 | 2010 | 71 | 0.370 |
Why?
|
Recombinant Proteins | 17 | 2022 | 6621 | 0.370 |
Why?
|
Thiophenes | 6 | 2013 | 589 | 0.360 |
Why?
|
Factor X | 10 | 2002 | 64 | 0.360 |
Why?
|
Factor XI | 4 | 2020 | 26 | 0.350 |
Why?
|
Accidental Falls | 2 | 2017 | 1062 | 0.350 |
Why?
|
Aortic Aneurysm, Abdominal | 1 | 2019 | 1186 | 0.350 |
Why?
|
Factor IXa | 6 | 2000 | 19 | 0.340 |
Why?
|
von Willebrand Diseases | 2 | 2023 | 127 | 0.330 |
Why?
|
Monitoring, Physiologic | 4 | 2013 | 1739 | 0.330 |
Why?
|
Protein C Deficiency | 8 | 2004 | 29 | 0.330 |
Why?
|
Homozygote | 7 | 2020 | 1787 | 0.330 |
Why?
|
Blood Coagulation Disorders | 8 | 2021 | 337 | 0.330 |
Why?
|
Cyclooxygenase Inhibitors | 1 | 2010 | 371 | 0.330 |
Why?
|
Polymorphism, Genetic | 7 | 2010 | 4328 | 0.320 |
Why?
|
Fibrinopeptide A | 16 | 2004 | 44 | 0.280 |
Why?
|
Coronary Disease | 13 | 2010 | 6077 | 0.280 |
Why?
|
Promoter Regions, Genetic | 5 | 2003 | 5867 | 0.270 |
Why?
|
Thrombophlebitis | 9 | 1994 | 309 | 0.270 |
Why?
|
Atrial Fibrillation | 7 | 2013 | 5035 | 0.260 |
Why?
|
Risk Factors | 45 | 2023 | 72296 | 0.260 |
Why?
|
Risk | 12 | 2020 | 9688 | 0.260 |
Why?
|
Platelet Aggregation Inhibitors | 2 | 2017 | 3070 | 0.260 |
Why?
|
Factor VIII | 8 | 2023 | 347 | 0.250 |
Why?
|
Vitamin K | 3 | 2013 | 295 | 0.240 |
Why?
|
Genetic Testing | 5 | 2010 | 3444 | 0.240 |
Why?
|
Male | 117 | 2021 | 350115 | 0.240 |
Why?
|
Hemostatics | 3 | 2023 | 229 | 0.240 |
Why?
|
von Willebrand Disease, Type 2 | 1 | 2023 | 8 | 0.240 |
Why?
|
Recurrence | 14 | 2019 | 8340 | 0.230 |
Why?
|
Female | 101 | 2023 | 380193 | 0.230 |
Why?
|
5' Flanking Region | 1 | 2003 | 31 | 0.230 |
Why?
|
Stroke | 8 | 2013 | 9981 | 0.230 |
Why?
|
Drug Administration Schedule | 12 | 2019 | 4933 | 0.230 |
Why?
|
Guidelines as Topic | 1 | 2010 | 1405 | 0.220 |
Why?
|
Disseminated Intravascular Coagulation | 12 | 2002 | 188 | 0.220 |
Why?
|
Receptors, Steroid | 1 | 2003 | 155 | 0.210 |
Why?
|
Phosphoproteins | 3 | 2003 | 2441 | 0.210 |
Why?
|
Patient Care Team | 3 | 2020 | 2531 | 0.210 |
Why?
|
Postoperative Complications | 15 | 2004 | 15297 | 0.200 |
Why?
|
Middle Aged | 87 | 2021 | 213390 | 0.200 |
Why?
|
Postthrombotic Syndrome | 1 | 2020 | 28 | 0.190 |
Why?
|
Mutation | 17 | 2004 | 29786 | 0.190 |
Why?
|
Myocardial Ischemia | 3 | 2004 | 2148 | 0.190 |
Why?
|
Mutagenesis, Insertional | 2 | 2001 | 655 | 0.190 |
Why?
|
Blood Platelets | 3 | 2010 | 2509 | 0.190 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 2 | 2021 | 5223 | 0.190 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2010 | 2282 | 0.190 |
Why?
|
Hematoma, Subdural, Spinal | 1 | 2020 | 8 | 0.190 |
Why?
|
Blood Coagulation Tests | 9 | 2018 | 263 | 0.180 |
Why?
|
Thrombocytopenia | 3 | 2008 | 1178 | 0.180 |
Why?
|
Patient Selection | 2 | 2020 | 4216 | 0.180 |
Why?
|
Aged | 62 | 2023 | 163288 | 0.180 |
Why?
|
Algorithms | 1 | 2020 | 13882 | 0.180 |
Why?
|
Knee | 1 | 2001 | 274 | 0.180 |
Why?
|
Hematoma, Epidural, Spinal | 1 | 2020 | 36 | 0.180 |
Why?
|
Embolectomy | 1 | 2020 | 120 | 0.170 |
Why?
|
Injections, Subcutaneous | 7 | 2009 | 667 | 0.170 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 3 | 2009 | 3873 | 0.170 |
Why?
|
DNA-Binding Proteins | 3 | 2003 | 9647 | 0.170 |
Why?
|
Quercetin | 1 | 2019 | 93 | 0.160 |
Why?
|
Intraoperative Period | 1 | 2019 | 520 | 0.160 |
Why?
|
Plasminogen | 4 | 2008 | 152 | 0.160 |
Why?
|
Vena Cava Filters | 2 | 2020 | 253 | 0.160 |
Why?
|
Pregnancy | 17 | 2017 | 29144 | 0.160 |
Why?
|
Antibodies, Antiphospholipid | 1 | 2018 | 69 | 0.160 |
Why?
|
Sp1 Transcription Factor | 1 | 1998 | 144 | 0.160 |
Why?
|
3' Untranslated Regions | 2 | 2001 | 513 | 0.160 |
Why?
|
Extracorporeal Membrane Oxygenation | 2 | 2020 | 1354 | 0.150 |
Why?
|
Neoplasms | 11 | 2020 | 21696 | 0.150 |
Why?
|
Clinical Trials, Phase III as Topic | 4 | 2007 | 841 | 0.150 |
Why?
|
Adult | 63 | 2020 | 214052 | 0.150 |
Why?
|
Binding Sites | 6 | 2003 | 6111 | 0.150 |
Why?
|
Protein Disulfide-Isomerases | 1 | 2019 | 198 | 0.150 |
Why?
|
Angina, Unstable | 5 | 2003 | 926 | 0.150 |
Why?
|
Fibrinogen | 9 | 2009 | 894 | 0.150 |
Why?
|
Acute Disease | 5 | 2020 | 7147 | 0.140 |
Why?
|
Pyridones | 2 | 2013 | 711 | 0.140 |
Why?
|
Time Factors | 20 | 2019 | 40075 | 0.140 |
Why?
|
Radioimmunoassay | 11 | 2002 | 919 | 0.140 |
Why?
|
Hormone Replacement Therapy | 1 | 2002 | 745 | 0.140 |
Why?
|
Pregnancy Complications, Cardiovascular | 2 | 2016 | 500 | 0.140 |
Why?
|
Transcription Factors | 3 | 2003 | 12207 | 0.140 |
Why?
|
Glycoproteins | 6 | 2005 | 2266 | 0.140 |
Why?
|
Hepatocyte Nuclear Factor 4 | 3 | 2003 | 118 | 0.140 |
Why?
|
Colistin | 1 | 2016 | 47 | 0.140 |
Why?
|
Arthroplasty, Replacement, Hip | 7 | 2008 | 1462 | 0.130 |
Why?
|
Mutation, Missense | 3 | 2006 | 2566 | 0.130 |
Why?
|
Genotype | 10 | 2010 | 12952 | 0.130 |
Why?
|
Double-Blind Method | 17 | 2019 | 12025 | 0.130 |
Why?
|
Organ Specificity | 1 | 2020 | 2008 | 0.130 |
Why?
|
Hemarthrosis | 1 | 2015 | 38 | 0.130 |
Why?
|
Thrombelastography | 1 | 2017 | 164 | 0.130 |
Why?
|
Abortion, Spontaneous | 2 | 2011 | 544 | 0.130 |
Why?
|
Biological Availability | 3 | 2011 | 397 | 0.130 |
Why?
|
Incidence | 12 | 2020 | 20952 | 0.130 |
Why?
|
Enzyme Inhibitors | 1 | 2006 | 3799 | 0.130 |
Why?
|
Lung Neoplasms | 2 | 2021 | 13104 | 0.120 |
Why?
|
Transfection | 6 | 2005 | 5895 | 0.120 |
Why?
|
Gram-Negative Bacteria | 1 | 2016 | 271 | 0.120 |
Why?
|
Factor VIIIa | 3 | 1995 | 16 | 0.120 |
Why?
|
Randomized Controlled Trials as Topic | 8 | 2013 | 9955 | 0.120 |
Why?
|
Gram-Negative Bacterial Infections | 1 | 2016 | 232 | 0.120 |
Why?
|
Fibrinolysis | 6 | 1995 | 322 | 0.120 |
Why?
|
Complement C1 Inhibitor Protein | 1 | 2014 | 97 | 0.120 |
Why?
|
Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 3 | 2003 | 315 | 0.120 |
Why?
|
DNA Mutational Analysis | 6 | 2001 | 4185 | 0.120 |
Why?
|
Poland | 3 | 2000 | 184 | 0.120 |
Why?
|
Blood Proteins | 3 | 2004 | 1124 | 0.110 |
Why?
|
Treatment Failure | 1 | 2019 | 2618 | 0.110 |
Why?
|
Pneumonia, Bacterial | 1 | 2016 | 316 | 0.110 |
Why?
|
Pedigree | 12 | 2000 | 4642 | 0.110 |
Why?
|
Haplotypes | 3 | 2010 | 2779 | 0.110 |
Why?
|
Heterozygote | 5 | 2009 | 2804 | 0.110 |
Why?
|
Factor XIa | 3 | 2000 | 8 | 0.110 |
Why?
|
Hematology | 1 | 2016 | 221 | 0.110 |
Why?
|
Heparitin Sulfate | 2 | 2008 | 225 | 0.110 |
Why?
|
Thrombectomy | 1 | 2017 | 680 | 0.110 |
Why?
|
Codon | 3 | 2000 | 611 | 0.110 |
Why?
|
Multiple Endocrine Neoplasia | 1 | 1992 | 25 | 0.110 |
Why?
|
Coronavirus Infections | 2 | 2020 | 3135 | 0.100 |
Why?
|
Review Literature as Topic | 1 | 2014 | 336 | 0.100 |
Why?
|
Pneumonia, Viral | 2 | 2020 | 3242 | 0.100 |
Why?
|
Heat-Shock Proteins | 1 | 1996 | 822 | 0.100 |
Why?
|
Treatment Outcome | 18 | 2019 | 63107 | 0.100 |
Why?
|
Trauma Centers | 1 | 2017 | 891 | 0.100 |
Why?
|
Transcription, Genetic | 2 | 2003 | 7721 | 0.100 |
Why?
|
Leukemia, Hairy Cell | 1 | 1992 | 82 | 0.100 |
Why?
|
Drug Resistance, Multiple, Bacterial | 1 | 2016 | 567 | 0.100 |
Why?
|
Cricetinae | 4 | 2005 | 2475 | 0.100 |
Why?
|
Meta-Analysis as Topic | 2 | 2009 | 1342 | 0.100 |
Why?
|
Drug Evaluation | 2 | 2010 | 647 | 0.100 |
Why?
|
Splenic Neoplasms | 1 | 1992 | 100 | 0.100 |
Why?
|
Abortion, Habitual | 2 | 2009 | 70 | 0.100 |
Why?
|
Immunoassay | 2 | 2005 | 752 | 0.100 |
Why?
|
Prodrugs | 1 | 2013 | 268 | 0.100 |
Why?
|
Pyrazoles | 2 | 2013 | 1972 | 0.100 |
Why?
|
Aged, 80 and over | 20 | 2020 | 57776 | 0.100 |
Why?
|
Helminth Proteins | 2 | 2002 | 171 | 0.100 |
Why?
|
International Normalized Ratio | 4 | 2006 | 367 | 0.100 |
Why?
|
Receptors, Cell Surface | 5 | 2009 | 2865 | 0.090 |
Why?
|
Contraceptive Agents, Female | 1 | 2012 | 135 | 0.090 |
Why?
|
CHO Cells | 3 | 1999 | 1409 | 0.090 |
Why?
|
Phlebography | 3 | 2009 | 333 | 0.090 |
Why?
|
Ketorolac | 1 | 2010 | 79 | 0.090 |
Why?
|
Progestins | 1 | 2012 | 306 | 0.090 |
Why?
|
Oligopeptides | 5 | 1988 | 1189 | 0.090 |
Why?
|
Blood Specimen Collection | 1 | 1991 | 246 | 0.090 |
Why?
|
Leukemia, Myelomonocytic, Acute | 1 | 1989 | 39 | 0.090 |
Why?
|
Enzyme Activation | 10 | 2007 | 3702 | 0.090 |
Why?
|
Hematoma | 1 | 2015 | 758 | 0.090 |
Why?
|
Myocardial Infarction | 9 | 2006 | 11718 | 0.090 |
Why?
|
Abruptio Placentae | 1 | 2011 | 118 | 0.090 |
Why?
|
Injections, Intravenous | 2 | 2010 | 1420 | 0.090 |
Why?
|
Antiphospholipid Syndrome | 1 | 2011 | 173 | 0.090 |
Why?
|
Leg | 1 | 2014 | 1116 | 0.090 |
Why?
|
Coagulation Protein Disorders | 1 | 2008 | 7 | 0.090 |
Why?
|
Genes, Reporter | 2 | 2003 | 1547 | 0.080 |
Why?
|
Men's Health | 1 | 2009 | 73 | 0.080 |
Why?
|
Platelet Function Tests | 1 | 2010 | 270 | 0.080 |
Why?
|
Anti-Arrhythmia Agents | 1 | 2013 | 789 | 0.080 |
Why?
|
Platelet Count | 2 | 2010 | 780 | 0.080 |
Why?
|
Societies, Medical | 3 | 2018 | 3743 | 0.080 |
Why?
|
Reference Values | 9 | 2009 | 4982 | 0.080 |
Why?
|
Coronary Artery Bypass | 2 | 2017 | 2288 | 0.080 |
Why?
|
Predictive Value of Tests | 5 | 2019 | 15078 | 0.080 |
Why?
|
Inpatients | 1 | 2020 | 2518 | 0.080 |
Why?
|
Stillbirth | 1 | 2011 | 346 | 0.080 |
Why?
|
Polymerase Chain Reaction | 6 | 2004 | 6171 | 0.080 |
Why?
|
Kallikrein-Kinin System | 1 | 2007 | 9 | 0.080 |
Why?
|
Prothrombin Time | 5 | 2008 | 119 | 0.080 |
Why?
|
Intermittent Pneumatic Compression Devices | 1 | 2007 | 25 | 0.080 |
Why?
|
Consanguinity | 2 | 2001 | 454 | 0.080 |
Why?
|
Gingivitis | 1 | 2008 | 124 | 0.080 |
Why?
|
Patient Discharge | 1 | 2020 | 3318 | 0.080 |
Why?
|
Critical Illness | 2 | 2021 | 2670 | 0.080 |
Why?
|
Immunoenzyme Techniques | 3 | 2007 | 1799 | 0.080 |
Why?
|
Antibodies | 2 | 2015 | 2460 | 0.070 |
Why?
|
Structure-Activity Relationship | 3 | 2003 | 3130 | 0.070 |
Why?
|
Arginine | 4 | 2008 | 944 | 0.070 |
Why?
|
Triglycerides | 4 | 2007 | 2453 | 0.070 |
Why?
|
Alleles | 5 | 2010 | 6933 | 0.070 |
Why?
|
Clinical Trials as Topic | 6 | 2013 | 7914 | 0.070 |
Why?
|
Hospital Mortality | 2 | 2020 | 5316 | 0.070 |
Why?
|
Aging | 5 | 2013 | 8664 | 0.070 |
Why?
|
Epinephrine | 1 | 2010 | 792 | 0.070 |
Why?
|
Referral and Consultation | 1 | 2020 | 3531 | 0.070 |
Why?
|
Cross-Over Studies | 2 | 2010 | 2029 | 0.070 |
Why?
|
Case-Control Studies | 9 | 2009 | 21748 | 0.070 |
Why?
|
Adolescent | 23 | 2020 | 85779 | 0.070 |
Why?
|
Surgical Procedures, Operative | 3 | 2007 | 1877 | 0.070 |
Why?
|
von Willebrand Factor | 4 | 2023 | 669 | 0.070 |
Why?
|
Antigens | 3 | 2005 | 1466 | 0.070 |
Why?
|
Area Under Curve | 1 | 2010 | 1655 | 0.070 |
Why?
|
Endotoxins | 2 | 2002 | 527 | 0.070 |
Why?
|
Cause of Death | 3 | 2020 | 3582 | 0.070 |
Why?
|
Prospective Studies | 14 | 2019 | 53290 | 0.070 |
Why?
|
Live Birth | 1 | 2009 | 512 | 0.070 |
Why?
|
Base Sequence | 6 | 1998 | 12797 | 0.070 |
Why?
|
Italy | 2 | 1999 | 832 | 0.060 |
Why?
|
Drug Delivery Systems | 2 | 2007 | 2219 | 0.060 |
Why?
|
Cricetulus | 2 | 1997 | 818 | 0.060 |
Why?
|
Polymorphism, Single Nucleotide | 3 | 2010 | 15520 | 0.060 |
Why?
|
Pennsylvania | 1 | 2006 | 613 | 0.060 |
Why?
|
Coagulants | 1 | 2004 | 49 | 0.060 |
Why?
|
Hirudins | 2 | 2008 | 183 | 0.060 |
Why?
|
Tumor Necrosis Factor-alpha | 4 | 1994 | 4424 | 0.060 |
Why?
|
Hematoma, Epidural, Cranial | 1 | 2004 | 60 | 0.060 |
Why?
|
Thrombospondin 1 | 1 | 2006 | 250 | 0.060 |
Why?
|
Platelet Factor 4 | 1 | 2004 | 129 | 0.060 |
Why?
|
Cardiology | 1 | 2016 | 1668 | 0.060 |
Why?
|
Digestive System Neoplasms | 1 | 2004 | 86 | 0.060 |
Why?
|
Retrospective Studies | 8 | 2022 | 77460 | 0.060 |
Why?
|
Postpartum Hemorrhage | 1 | 2008 | 258 | 0.060 |
Why?
|
Molecular Epidemiology | 1 | 2006 | 468 | 0.060 |
Why?
|
Coumarins | 2 | 1995 | 119 | 0.060 |
Why?
|
Risk Assessment | 9 | 2020 | 23336 | 0.060 |
Why?
|
COUP Transcription Factors | 1 | 2003 | 4 | 0.060 |
Why?
|
Exons | 2 | 2003 | 2439 | 0.060 |
Why?
|
Prognosis | 5 | 2020 | 29060 | 0.060 |
Why?
|
Practice Guidelines as Topic | 4 | 2016 | 7282 | 0.060 |
Why?
|
COUP Transcription Factor II | 1 | 2003 | 18 | 0.060 |
Why?
|
Hospitals | 1 | 2017 | 3954 | 0.060 |
Why?
|
DNA, Complementary | 2 | 1997 | 2050 | 0.060 |
Why?
|
Dose-Response Relationship, Drug | 7 | 2019 | 10943 | 0.060 |
Why?
|
Intracranial Embolism and Thrombosis | 2 | 1993 | 148 | 0.060 |
Why?
|
Factor XI Deficiency | 2 | 1994 | 18 | 0.060 |
Why?
|
Cloning, Molecular | 2 | 2001 | 4320 | 0.050 |
Why?
|
Genetic Markers | 1 | 2009 | 2634 | 0.050 |
Why?
|
Genital Diseases, Female | 1 | 2004 | 197 | 0.050 |
Why?
|
Cerebral Hemorrhage | 2 | 2013 | 2647 | 0.050 |
Why?
|
Animals | 23 | 2014 | 168768 | 0.050 |
Why?
|
Curriculum | 1 | 2016 | 3605 | 0.050 |
Why?
|
Hormones | 1 | 2006 | 889 | 0.050 |
Why?
|
Selectins | 1 | 2002 | 102 | 0.050 |
Why?
|
Young Adult | 6 | 2020 | 56429 | 0.050 |
Why?
|
Follow-Up Studies | 10 | 2020 | 39052 | 0.050 |
Why?
|
Protein S | 4 | 1992 | 30 | 0.050 |
Why?
|
Collagen | 1 | 2010 | 2688 | 0.050 |
Why?
|
Bleomycin | 1 | 1983 | 512 | 0.050 |
Why?
|
Response Elements | 1 | 2003 | 312 | 0.050 |
Why?
|
Aspirin | 3 | 2010 | 3283 | 0.050 |
Why?
|
Pre-Eclampsia | 1 | 2011 | 1200 | 0.050 |
Why?
|
Asparaginase | 1 | 1983 | 236 | 0.050 |
Why?
|
Leukemia, Myeloid, Acute | 2 | 1989 | 3524 | 0.050 |
Why?
|
Registries | 1 | 2017 | 8091 | 0.050 |
Why?
|
Flow Cytometry | 2 | 2009 | 5974 | 0.050 |
Why?
|
Pentachlorophenol | 1 | 2001 | 10 | 0.050 |
Why?
|
Receptors, Glucocorticoid | 1 | 2003 | 302 | 0.050 |
Why?
|
Angina Pectoris | 3 | 2000 | 977 | 0.050 |
Why?
|
DNA | 6 | 2005 | 7294 | 0.050 |
Why?
|
Health Knowledge, Attitudes, Practice | 2 | 2013 | 3922 | 0.050 |
Why?
|
Antigens, CD | 2 | 2009 | 4026 | 0.050 |
Why?
|
HeLa Cells | 2 | 1998 | 3130 | 0.050 |
Why?
|
Abdomen | 1 | 2007 | 1118 | 0.050 |
Why?
|
Base Pair Mismatch | 1 | 2001 | 97 | 0.050 |
Why?
|
Prevalence | 5 | 2013 | 15221 | 0.050 |
Why?
|
Peptide Hydrolases | 2 | 2002 | 634 | 0.050 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2003 | 629 | 0.050 |
Why?
|
Introns | 1 | 2003 | 992 | 0.050 |
Why?
|
Cells, Cultured | 3 | 2003 | 19233 | 0.050 |
Why?
|
Hydrogen Bonding | 1 | 2001 | 291 | 0.050 |
Why?
|
Critical Care | 1 | 2013 | 2647 | 0.050 |
Why?
|
Receptor Protein-Tyrosine Kinases | 2 | 2021 | 1660 | 0.050 |
Why?
|
Polymorphism, Single-Stranded Conformational | 2 | 2004 | 335 | 0.050 |
Why?
|
Tissue Plasminogen Activator | 2 | 2001 | 1261 | 0.050 |
Why?
|
Cohort Studies | 8 | 2016 | 40559 | 0.050 |
Why?
|
Clinical Competence | 1 | 2016 | 4687 | 0.050 |
Why?
|
Family | 2 | 2010 | 3147 | 0.040 |
Why?
|
Plasminogen Activator Inhibitor 1 | 1 | 2001 | 281 | 0.040 |
Why?
|
Cross Reactions | 1 | 2001 | 841 | 0.040 |
Why?
|
Molecular Sequence Data | 5 | 1996 | 18111 | 0.040 |
Why?
|
Protein S Deficiency | 2 | 1996 | 16 | 0.040 |
Why?
|
Blood Coagulation Factor Inhibitors | 1 | 1999 | 16 | 0.040 |
Why?
|
Oligodeoxyribonucleotides | 1 | 2000 | 708 | 0.040 |
Why?
|
Binding, Competitive | 1 | 2000 | 1157 | 0.040 |
Why?
|
Inflammation | 5 | 2020 | 10637 | 0.040 |
Why?
|
Factor V Deficiency | 2 | 1996 | 13 | 0.040 |
Why?
|
Withholding Treatment | 2 | 2015 | 599 | 0.040 |
Why?
|
Disease Susceptibility | 4 | 2007 | 1782 | 0.040 |
Why?
|
Sex Factors | 4 | 2019 | 10400 | 0.040 |
Why?
|
Models, Statistical | 3 | 2009 | 5101 | 0.040 |
Why?
|
Data Interpretation, Statistical | 1 | 2009 | 2716 | 0.040 |
Why?
|
Frameshift Mutation | 1 | 2000 | 399 | 0.040 |
Why?
|
Evaluation Studies as Topic | 1 | 2001 | 1681 | 0.040 |
Why?
|
Decision Support Techniques | 1 | 2008 | 1956 | 0.040 |
Why?
|
Partial Thromboplastin Time | 2 | 2001 | 206 | 0.040 |
Why?
|
Pesticides | 1 | 2001 | 287 | 0.040 |
Why?
|
Protein Structure, Tertiary | 2 | 2006 | 3848 | 0.040 |
Why?
|
Post-Exposure Prophylaxis | 1 | 2018 | 102 | 0.040 |
Why?
|
Pyridines | 1 | 2010 | 2825 | 0.040 |
Why?
|
Endothelium, Vascular | 3 | 2020 | 4459 | 0.040 |
Why?
|
Anti-Bacterial Agents | 1 | 2016 | 7182 | 0.040 |
Why?
|
Tomography, X-Ray Computed | 2 | 2020 | 20130 | 0.040 |
Why?
|
Biomedical Research | 1 | 2013 | 3309 | 0.040 |
Why?
|
Nuclear Family | 1 | 1999 | 318 | 0.040 |
Why?
|
Emergency Service, Hospital | 1 | 2017 | 7658 | 0.040 |
Why?
|
Intention to Treat Analysis | 1 | 2019 | 426 | 0.040 |
Why?
|
Reagent Kits, Diagnostic | 1 | 1999 | 224 | 0.040 |
Why?
|
Disease-Free Survival | 2 | 2006 | 6896 | 0.040 |
Why?
|
Valine | 1 | 1999 | 413 | 0.040 |
Why?
|
Jews | 1 | 1999 | 385 | 0.040 |
Why?
|
Dietary Fats | 3 | 2007 | 2016 | 0.040 |
Why?
|
Immunologic Deficiency Syndromes | 1 | 2001 | 547 | 0.040 |
Why?
|
Neoplasm Proteins | 1 | 1989 | 3707 | 0.040 |
Why?
|
Alanine | 1 | 1999 | 572 | 0.040 |
Why?
|
Decision Making | 1 | 2011 | 3888 | 0.040 |
Why?
|
Safety | 1 | 2002 | 1186 | 0.040 |
Why?
|
Hip Fractures | 2 | 2002 | 955 | 0.040 |
Why?
|
Pan troglodytes | 4 | 2002 | 229 | 0.040 |
Why?
|
Ultrasonography | 1 | 2010 | 5984 | 0.040 |
Why?
|
Infusions, Parenteral | 2 | 2008 | 419 | 0.040 |
Why?
|
Acute Coronary Syndrome | 1 | 2010 | 2337 | 0.030 |
Why?
|
Pregnancy Outcome | 1 | 2007 | 2795 | 0.030 |
Why?
|
Genetic Predisposition to Disease | 5 | 2009 | 17446 | 0.030 |
Why?
|
Virus Internalization | 1 | 2020 | 502 | 0.030 |
Why?
|
Basal Metabolism | 1 | 1997 | 168 | 0.030 |
Why?
|
Lipids | 1 | 2007 | 3307 | 0.030 |
Why?
|
Myositis | 1 | 1979 | 251 | 0.030 |
Why?
|
Epidermal Growth Factor | 1 | 1999 | 709 | 0.030 |
Why?
|
Antibody Formation | 1 | 2001 | 1402 | 0.030 |
Why?
|
Myeloproliferative Disorders | 1 | 2002 | 606 | 0.030 |
Why?
|
Liver Neoplasms | 1 | 1992 | 4253 | 0.030 |
Why?
|
Amino Acid Substitution | 1 | 2000 | 1793 | 0.030 |
Why?
|
Saphenous Vein | 1 | 1999 | 532 | 0.030 |
Why?
|
Fibrin | 4 | 1995 | 506 | 0.030 |
Why?
|
Gene Rearrangement | 1 | 2021 | 1179 | 0.030 |
Why?
|
Streptokinase | 1 | 1995 | 188 | 0.030 |
Why?
|
Cerebrovascular Disorders | 2 | 1993 | 1504 | 0.030 |
Why?
|
Proto-Oncogene Proteins | 2 | 2021 | 4554 | 0.030 |
Why?
|
Estrogen Replacement Therapy | 2 | 2012 | 1203 | 0.030 |
Why?
|
Renin-Angiotensin System | 1 | 2020 | 758 | 0.030 |
Why?
|
Homocysteine | 1 | 1999 | 647 | 0.030 |
Why?
|
Evidence-Based Medicine | 3 | 2018 | 3611 | 0.030 |
Why?
|
COS Cells | 1 | 1997 | 1161 | 0.030 |
Why?
|
Bloodletting | 1 | 1995 | 23 | 0.030 |
Why?
|
Erythrocyte Transfusion | 1 | 2020 | 565 | 0.030 |
Why?
|
Adaptive Immunity | 1 | 2020 | 714 | 0.030 |
Why?
|
Stockings, Compression | 1 | 2015 | 37 | 0.030 |
Why?
|
Postprandial Period | 1 | 1996 | 292 | 0.030 |
Why?
|
Proportional Hazards Models | 3 | 2005 | 12356 | 0.030 |
Why?
|
Sequence Analysis, DNA | 1 | 2006 | 4805 | 0.030 |
Why?
|
Survival Rate | 2 | 2021 | 12788 | 0.030 |
Why?
|
Hemodilution | 1 | 1995 | 114 | 0.030 |
Why?
|
Isotonic Solutions | 1 | 1995 | 119 | 0.030 |
Why?
|
Ventricular Dysfunction, Right | 1 | 2020 | 581 | 0.030 |
Why?
|
Immunity, Cellular | 1 | 2001 | 1607 | 0.030 |
Why?
|
Purpura | 1 | 1995 | 122 | 0.030 |
Why?
|
Coronary Artery Disease | 3 | 2007 | 6486 | 0.030 |
Why?
|
Intracranial Hemorrhages | 1 | 2020 | 855 | 0.030 |
Why?
|
Blood Component Transfusion | 1 | 1995 | 143 | 0.030 |
Why?
|
Clinical Laboratory Techniques | 1 | 1999 | 738 | 0.030 |
Why?
|
Genetic Variation | 1 | 2009 | 6542 | 0.030 |
Why?
|
Cardiovascular Diseases | 3 | 2007 | 15160 | 0.030 |
Why?
|
Polycythemia | 1 | 1995 | 126 | 0.030 |
Why?
|
Pentoxifylline | 1 | 1994 | 55 | 0.030 |
Why?
|
Nucleic Acid Heteroduplexes | 1 | 1993 | 47 | 0.030 |
Why?
|
Necrosis | 2 | 1995 | 1643 | 0.030 |
Why?
|
Boston | 1 | 2007 | 9312 | 0.030 |
Why?
|
Angioedemas, Hereditary | 1 | 2014 | 91 | 0.030 |
Why?
|
Gene Transfer Techniques | 1 | 1999 | 1225 | 0.030 |
Why?
|
Polymorphism, Restriction Fragment Length | 1 | 1994 | 769 | 0.030 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 1989 | 8432 | 0.030 |
Why?
|
Infusions, Intravenous | 5 | 2000 | 2274 | 0.030 |
Why?
|
Electrophoresis, Polyacrylamide Gel | 4 | 2001 | 1801 | 0.030 |
Why?
|
Geography | 1 | 2016 | 669 | 0.030 |
Why?
|
Child | 9 | 2006 | 77709 | 0.030 |
Why?
|
Glycosylation | 1 | 1996 | 1128 | 0.030 |
Why?
|
Immunoglobulin M | 1 | 2018 | 1537 | 0.030 |
Why?
|
Drug Therapy, Combination | 3 | 2016 | 6489 | 0.030 |
Why?
|
Protein Conformation | 1 | 2001 | 4010 | 0.030 |
Why?
|
Lung Diseases | 1 | 1983 | 1887 | 0.030 |
Why?
|
Gemfibrozil | 1 | 1992 | 30 | 0.030 |
Why?
|
Protein Folding | 1 | 1996 | 840 | 0.030 |
Why?
|
Puerperal Disorders | 1 | 1995 | 275 | 0.030 |
Why?
|
Abnormalities, Drug-Induced | 1 | 1995 | 317 | 0.030 |
Why?
|
Gene Expression | 3 | 2005 | 7798 | 0.030 |
Why?
|
Intrauterine Devices, Medicated | 1 | 2012 | 28 | 0.030 |
Why?
|
Placebos | 2 | 2007 | 1676 | 0.030 |
Why?
|
Drug Eruptions | 1 | 1995 | 297 | 0.030 |
Why?
|
Enkephalin, Methionine | 1 | 1991 | 26 | 0.030 |
Why?
|
Recombinant Fusion Proteins | 1 | 2001 | 3773 | 0.030 |
Why?
|
Fibrinogens, Abnormal | 1 | 1991 | 10 | 0.030 |
Why?
|
Carrier Proteins | 2 | 1996 | 5023 | 0.030 |
Why?
|
Natriuretic Peptide, Brain | 1 | 2020 | 1572 | 0.030 |
Why?
|
Multiple Organ Failure | 1 | 1994 | 389 | 0.030 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2021 | 2455 | 0.030 |
Why?
|
Vincristine | 2 | 1984 | 1039 | 0.030 |
Why?
|
Glutamine | 1 | 1994 | 579 | 0.020 |
Why?
|
Lipoproteins | 1 | 1996 | 878 | 0.020 |
Why?
|
Molecular Chaperones | 1 | 1996 | 743 | 0.020 |
Why?
|
Environmental Pollutants | 1 | 2001 | 1179 | 0.020 |
Why?
|
RNA Splicing | 1 | 1996 | 908 | 0.020 |
Why?
|
Plasminogen Inactivators | 1 | 1990 | 38 | 0.020 |
Why?
|
Phospholipids | 1 | 1995 | 784 | 0.020 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2003 | 2214 | 0.020 |
Why?
|
Estrogens, Conjugated (USP) | 1 | 1992 | 275 | 0.020 |
Why?
|
Cell-Derived Microparticles | 1 | 2012 | 168 | 0.020 |
Why?
|
Syndrome | 1 | 1997 | 3252 | 0.020 |
Why?
|
Contraceptives, Oral, Hormonal | 1 | 2012 | 188 | 0.020 |
Why?
|
Postpartum Period | 1 | 2017 | 1086 | 0.020 |
Why?
|
Models, Molecular | 1 | 2001 | 5451 | 0.020 |
Why?
|
Receptors, Thrombin | 2 | 1987 | 131 | 0.020 |
Why?
|
Accreditation | 1 | 2013 | 452 | 0.020 |
Why?
|
Transcriptional Activation | 1 | 1997 | 1783 | 0.020 |
Why?
|
Endoplasmic Reticulum | 1 | 1996 | 1146 | 0.020 |
Why?
|
Pandemics | 2 | 2020 | 8385 | 0.020 |
Why?
|
Immune Sera | 1 | 1990 | 641 | 0.020 |
Why?
|
Chromogenic Compounds | 2 | 2002 | 30 | 0.020 |
Why?
|
DNA Primers | 1 | 1994 | 2891 | 0.020 |
Why?
|
Sequence Deletion | 1 | 1994 | 1525 | 0.020 |
Why?
|
Hospitalization | 2 | 2020 | 10259 | 0.020 |
Why?
|
Immunoglobulin G | 3 | 2018 | 4561 | 0.020 |
Why?
|
Hot Temperature | 1 | 1995 | 1356 | 0.020 |
Why?
|
Peptides | 1 | 2002 | 4410 | 0.020 |
Why?
|
Critical Pathways | 1 | 2013 | 476 | 0.020 |
Why?
|
Autoantibodies | 1 | 2018 | 2036 | 0.020 |
Why?
|
Chromatography, High Pressure Liquid | 3 | 1992 | 1572 | 0.020 |
Why?
|
Calcium | 2 | 2001 | 5755 | 0.020 |
Why?
|
Cell Nucleus | 1 | 1998 | 2969 | 0.020 |
Why?
|
Amyloid beta-Protein Precursor | 1 | 1995 | 1121 | 0.020 |
Why?
|
Uterine Cervicitis | 1 | 2008 | 30 | 0.020 |
Why?
|
International Cooperation | 1 | 2016 | 1420 | 0.020 |
Why?
|
Postoperative Care | 3 | 2002 | 1487 | 0.020 |
Why?
|
Antibodies, Monoclonal | 4 | 1994 | 9274 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2019 | 5077 | 0.020 |
Why?
|
Models, Biological | 3 | 2008 | 9584 | 0.020 |
Why?
|
Delayed-Action Preparations | 1 | 2012 | 968 | 0.020 |
Why?
|
Dermatan Sulfate | 1 | 2008 | 35 | 0.020 |
Why?
|
Plasminogen Activators | 2 | 1994 | 209 | 0.020 |
Why?
|
Protein Binding | 4 | 2006 | 9384 | 0.020 |
Why?
|
Logistic Models | 2 | 2020 | 13409 | 0.020 |
Why?
|
Histidine | 1 | 1989 | 313 | 0.020 |
Why?
|
Multicenter Studies as Topic | 2 | 2004 | 1677 | 0.020 |
Why?
|
Kinetics | 4 | 2002 | 6476 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2019 | 6539 | 0.020 |
Why?
|
Protein Processing, Post-Translational | 1 | 1996 | 1988 | 0.020 |
Why?
|
Secondary Prevention | 2 | 2006 | 1530 | 0.020 |
Why?
|
Chondroitin Sulfates | 1 | 2008 | 187 | 0.020 |
Why?
|
Pipecolic Acids | 1 | 2008 | 76 | 0.020 |
Why?
|
Heart Ventricles | 1 | 2020 | 3817 | 0.020 |
Why?
|
Child, Preschool | 4 | 2004 | 41005 | 0.020 |
Why?
|
Enzyme Precursors | 1 | 1987 | 176 | 0.020 |
Why?
|
Chemistry | 1 | 1987 | 352 | 0.020 |
Why?
|
London | 1 | 2007 | 233 | 0.020 |
Why?
|
Echocardiography | 1 | 2020 | 5099 | 0.020 |
Why?
|
Dogs | 2 | 1989 | 3912 | 0.020 |
Why?
|
Intensive Care Units | 1 | 2021 | 3680 | 0.020 |
Why?
|
Chromosomes, Human, X | 1 | 2009 | 296 | 0.020 |
Why?
|
Chemical Phenomena | 1 | 1987 | 518 | 0.020 |
Why?
|
Protein Precursors | 1 | 1991 | 1154 | 0.020 |
Why?
|
Doxorubicin | 2 | 1984 | 2234 | 0.020 |
Why?
|
Epidemiologic Methods | 1 | 2012 | 1364 | 0.020 |
Why?
|
Odds Ratio | 2 | 2010 | 9849 | 0.020 |
Why?
|
Upper Extremity | 1 | 2012 | 648 | 0.020 |
Why?
|
Cysteine | 1 | 1991 | 873 | 0.020 |
Why?
|
Cesarean Section | 2 | 2008 | 1365 | 0.020 |
Why?
|
Length of Stay | 1 | 2020 | 6311 | 0.020 |
Why?
|
RNA, Neoplasm | 1 | 1989 | 769 | 0.020 |
Why?
|
Chromatography, Affinity | 2 | 1987 | 549 | 0.020 |
Why?
|
Cell Line, Tumor | 1 | 2003 | 16690 | 0.020 |
Why?
|
Factor X Deficiency | 1 | 1986 | 9 | 0.020 |
Why?
|
Ischemic Attack, Transient | 1 | 1992 | 935 | 0.020 |
Why?
|
United States | 4 | 2021 | 69872 | 0.020 |
Why?
|
Continuity of Patient Care | 1 | 2013 | 1049 | 0.020 |
Why?
|
Patient Readmission | 1 | 2020 | 3116 | 0.020 |
Why?
|
Mass Screening | 1 | 2001 | 5253 | 0.020 |
Why?
|
Subarachnoid Hemorrhage, Traumatic | 1 | 2004 | 12 | 0.020 |
Why?
|
Nonlinear Dynamics | 1 | 2008 | 502 | 0.020 |
Why?
|
Analysis of Variance | 2 | 2009 | 6366 | 0.020 |
Why?
|
Cell Membrane | 1 | 1995 | 3749 | 0.020 |
Why?
|
Pregnancy Complications | 1 | 1979 | 2861 | 0.020 |
Why?
|
Albumins | 1 | 2007 | 568 | 0.020 |
Why?
|
alpha 1-Antitrypsin | 1 | 1985 | 163 | 0.020 |
Why?
|
Catalysis | 2 | 2002 | 762 | 0.020 |
Why?
|
Gingival Diseases | 1 | 2004 | 34 | 0.020 |
Why?
|
Menopause | 1 | 1992 | 1626 | 0.020 |
Why?
|
Massachusetts | 1 | 2017 | 8662 | 0.020 |
Why?
|
Linkage Disequilibrium | 1 | 2009 | 1997 | 0.010 |
Why?
|
Hematoma, Subdural | 1 | 2004 | 126 | 0.010 |
Why?
|
Premedication | 1 | 2004 | 258 | 0.010 |
Why?
|
Cell Separation | 1 | 2009 | 1751 | 0.010 |
Why?
|
Laminectomy | 1 | 2004 | 234 | 0.010 |
Why?
|
Leukocyte Count | 1 | 2007 | 1588 | 0.010 |
Why?
|
Disease Progression | 1 | 2020 | 13286 | 0.010 |
Why?
|
Prednisolone | 1 | 1984 | 334 | 0.010 |
Why?
|
Tissue Distribution | 1 | 2008 | 2327 | 0.010 |
Why?
|
Intracranial Thrombosis | 1 | 2004 | 113 | 0.010 |
Why?
|
Canada | 1 | 2009 | 2065 | 0.010 |
Why?
|
Lipoproteins, HDL | 1 | 2007 | 638 | 0.010 |
Why?
|
Hemorrhagic Disorders | 1 | 2002 | 36 | 0.010 |
Why?
|
Preoperative Care | 2 | 2002 | 2251 | 0.010 |
Why?
|
Research | 2 | 2007 | 1999 | 0.010 |
Why?
|
Ear Diseases | 1 | 2004 | 170 | 0.010 |
Why?
|
Leukocytes, Mononuclear | 1 | 1989 | 1837 | 0.010 |
Why?
|
Macaca fascicularis | 1 | 1984 | 915 | 0.010 |
Why?
|
Cytarabine | 1 | 1984 | 692 | 0.010 |
Why?
|
Sterilization, Tubal | 1 | 2003 | 87 | 0.010 |
Why?
|
Amino Acid Sequence | 4 | 1991 | 13814 | 0.010 |
Why?
|
Brain Infarction | 1 | 2004 | 299 | 0.010 |
Why?
|
Risk Reduction Behavior | 1 | 2009 | 1125 | 0.010 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 1983 | 11525 | 0.010 |
Why?
|
Life Expectancy | 1 | 2008 | 1184 | 0.010 |
Why?
|
Hematopoietic Stem Cells | 1 | 1994 | 3390 | 0.010 |
Why?
|
Gene Frequency | 1 | 2009 | 3587 | 0.010 |
Why?
|
Cell Culture Techniques | 1 | 2009 | 1678 | 0.010 |
Why?
|
Inheritance Patterns | 1 | 2004 | 340 | 0.010 |
Why?
|
Comorbidity | 2 | 2007 | 10388 | 0.010 |
Why?
|
Atherectomy, Coronary | 1 | 2001 | 148 | 0.010 |
Why?
|
Vinblastine | 1 | 1983 | 502 | 0.010 |
Why?
|
Regression Analysis | 2 | 2002 | 6459 | 0.010 |
Why?
|
Endpoint Determination | 1 | 2004 | 601 | 0.010 |
Why?
|
Splenectomy | 1 | 2003 | 395 | 0.010 |
Why?
|
Sepsis | 2 | 1993 | 2593 | 0.010 |
Why?
|
Leucovorin | 1 | 1983 | 628 | 0.010 |
Why?
|
Neopterin | 1 | 2001 | 56 | 0.010 |
Why?
|
Thrombocythemia, Essential | 1 | 2002 | 105 | 0.010 |
Why?
|
Endotoxemia | 1 | 2002 | 207 | 0.010 |
Why?
|
Knee Prosthesis | 1 | 2004 | 425 | 0.010 |
Why?
|
Smoking | 1 | 1998 | 8987 | 0.010 |
Why?
|
Disease Models, Animal | 2 | 2014 | 18034 | 0.010 |
Why?
|
Polycythemia Vera | 1 | 2002 | 164 | 0.010 |
Why?
|
Complement C1 Inactivator Proteins | 1 | 2000 | 93 | 0.010 |
Why?
|
Solubility | 1 | 2002 | 1088 | 0.010 |
Why?
|
ROC Curve | 2 | 2000 | 3528 | 0.010 |
Why?
|
Central Nervous System Diseases | 1 | 2004 | 518 | 0.010 |
Why?
|
Polymers | 1 | 1987 | 1621 | 0.010 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2015 | 3255 | 0.010 |
Why?
|
Survival Analysis | 1 | 2012 | 10252 | 0.010 |
Why?
|
Skin | 1 | 1993 | 4372 | 0.010 |
Why?
|
Sensitivity and Specificity | 2 | 2009 | 14723 | 0.010 |
Why?
|
Guideline Adherence | 1 | 2010 | 2265 | 0.010 |
Why?
|
Autoanalysis | 1 | 1999 | 72 | 0.010 |
Why?
|
Bone Marrow | 1 | 1989 | 2948 | 0.010 |
Why?
|
Research Support as Topic | 1 | 2003 | 705 | 0.010 |
Why?
|
Molecular Weight | 3 | 1987 | 2255 | 0.010 |
Why?
|
Microspheres | 1 | 2001 | 777 | 0.010 |
Why?
|
Family Characteristics | 1 | 2004 | 1000 | 0.010 |
Why?
|
Family Health | 1 | 2004 | 1281 | 0.010 |
Why?
|
Pulmonary Fibrosis | 1 | 1983 | 530 | 0.010 |
Why?
|
RNA, Messenger | 2 | 1994 | 13035 | 0.010 |
Why?
|
Remission, Spontaneous | 1 | 1979 | 382 | 0.010 |
Why?
|
Sulfonamides | 1 | 2008 | 1940 | 0.010 |
Why?
|
Germany | 1 | 2001 | 862 | 0.010 |
Why?
|
Lymphocyte Count | 1 | 2001 | 793 | 0.010 |
Why?
|
Hip Prosthesis | 1 | 2004 | 917 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 1997 | 12073 | 0.010 |
Why?
|
Drug Interactions | 1 | 1983 | 1460 | 0.010 |
Why?
|
Genetic Linkage | 1 | 2004 | 2421 | 0.010 |
Why?
|
Infant, Newborn | 2 | 1995 | 25628 | 0.010 |
Why?
|
Quality of Health Care | 1 | 2013 | 4369 | 0.010 |
Why?
|
Drug Industry | 1 | 2003 | 746 | 0.010 |
Why?
|
Leiomyoma | 1 | 2003 | 730 | 0.010 |
Why?
|
Cyclophosphamide | 1 | 1983 | 2242 | 0.010 |
Why?
|
Vascular Diseases | 1 | 2005 | 1161 | 0.010 |
Why?
|
Hysterectomy | 1 | 2003 | 927 | 0.010 |
Why?
|
Cisplatin | 1 | 1983 | 1662 | 0.010 |
Why?
|
Testicular Neoplasms | 1 | 1983 | 806 | 0.010 |
Why?
|
Confidence Intervals | 1 | 2002 | 2971 | 0.010 |
Why?
|
Methotrexate | 1 | 1983 | 1728 | 0.010 |
Why?
|
Biocompatible Materials | 1 | 1985 | 1736 | 0.010 |
Why?
|
Volatilization | 1 | 1995 | 82 | 0.010 |
Why?
|
Factor Va | 1 | 1995 | 10 | 0.010 |
Why?
|
Fracture Fixation, Internal | 1 | 2002 | 917 | 0.010 |
Why?
|
C-Reactive Protein | 1 | 2007 | 3778 | 0.010 |
Why?
|
Biological Assay | 1 | 1999 | 652 | 0.010 |
Why?
|
Dexamethasone | 1 | 1983 | 1951 | 0.010 |
Why?
|
Antineoplastic Agents | 1 | 2019 | 13693 | 0.010 |
Why?
|
Protease Nexins | 1 | 1995 | 40 | 0.010 |
Why?
|
Computer Simulation | 1 | 2009 | 6194 | 0.010 |
Why?
|
Aortic Diseases | 1 | 1981 | 743 | 0.010 |
Why?
|
Blood Viscosity | 1 | 1995 | 124 | 0.010 |
Why?
|
Platelet Aggregation | 2 | 1991 | 798 | 0.010 |
Why?
|
Anus Diseases | 1 | 1994 | 59 | 0.010 |
Why?
|
Environmental Monitoring | 1 | 2001 | 1414 | 0.010 |
Why?
|
Kidney Diseases | 1 | 1985 | 2148 | 0.010 |
Why?
|
Age Factors | 2 | 2008 | 18373 | 0.010 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2001 | 4751 | 0.010 |
Why?
|
Uterine Hemorrhage | 1 | 1995 | 255 | 0.010 |
Why?
|
Lymphoma | 1 | 1983 | 1877 | 0.010 |
Why?
|
Phosphatidylserines | 1 | 1995 | 193 | 0.010 |
Why?
|
Uterine Neoplasms | 1 | 2003 | 1513 | 0.010 |
Why?
|
Fatigue | 1 | 2001 | 1531 | 0.010 |
Why?
|
Electrophoresis | 1 | 1993 | 240 | 0.010 |
Why?
|
Hematocrit | 1 | 1995 | 636 | 0.010 |
Why?
|
Blood Volume | 1 | 1995 | 565 | 0.010 |
Why?
|
Osmolar Concentration | 1 | 1994 | 683 | 0.010 |
Why?
|
Respiratory Tract Infections | 1 | 2001 | 961 | 0.010 |
Why?
|
Phosphatidylcholines | 1 | 1995 | 411 | 0.010 |
Why?
|
Tooth Extraction | 1 | 1994 | 222 | 0.010 |
Why?
|
Granulocytes | 1 | 1994 | 548 | 0.010 |
Why?
|
Databases, Factual | 1 | 2007 | 7730 | 0.010 |
Why?
|
Fibrinopeptide B | 1 | 1991 | 4 | 0.010 |
Why?
|
Immunosorbent Techniques | 1 | 1992 | 184 | 0.010 |
Why?
|
Cost-Benefit Analysis | 1 | 2004 | 5388 | 0.010 |
Why?
|
Delivery, Obstetric | 1 | 1979 | 906 | 0.010 |
Why?
|
Blood Loss, Surgical | 1 | 1995 | 662 | 0.010 |
Why?
|
Appendectomy | 1 | 1994 | 401 | 0.010 |
Why?
|
alpha-Macroglobulins | 1 | 1990 | 64 | 0.010 |
Why?
|
fms-Like Tyrosine Kinase 3 | 1 | 1994 | 491 | 0.010 |
Why?
|
Prekallikrein | 1 | 1990 | 11 | 0.010 |
Why?
|
Fibrinolysin | 1 | 1990 | 131 | 0.010 |
Why?
|
Factor XII | 1 | 1990 | 19 | 0.010 |
Why?
|
Radiography | 1 | 2001 | 7023 | 0.010 |
Why?
|
Intraoperative Care | 1 | 1994 | 767 | 0.010 |
Why?
|
Brain Ischemia | 1 | 2004 | 3265 | 0.010 |
Why?
|
Mortality | 1 | 2001 | 2864 | 0.010 |
Why?
|
Antithrombin Proteins | 1 | 1989 | 9 | 0.010 |
Why?
|
Crotalid Venoms | 1 | 1989 | 28 | 0.010 |
Why?
|
Electrocardiography | 1 | 2003 | 6442 | 0.010 |
Why?
|
Urokinase-Type Plasminogen Activator | 1 | 1990 | 336 | 0.010 |
Why?
|
Vermont | 1 | 1989 | 85 | 0.010 |
Why?
|
Methods | 1 | 1989 | 1129 | 0.010 |
Why?
|
Cysts | 1 | 1994 | 678 | 0.010 |
Why?
|
Macromolecular Substances | 1 | 1991 | 1454 | 0.010 |
Why?
|
Trypsin | 1 | 1989 | 511 | 0.010 |
Why?
|
Infant | 2 | 2004 | 35134 | 0.000 |
Why?
|
Mutagenesis, Site-Directed | 1 | 1992 | 1723 | 0.000 |
Why?
|
Depression, Chemical | 1 | 1987 | 191 | 0.000 |
Why?
|
Research Design | 1 | 2003 | 5984 | 0.000 |
Why?
|
Immunoelectrophoresis | 1 | 1987 | 110 | 0.000 |
Why?
|
Chronic Disease | 1 | 2002 | 9145 | 0.000 |
Why?
|
Cell Division | 1 | 1994 | 4569 | 0.000 |
Why?
|
Bone Marrow Cells | 1 | 1994 | 2513 | 0.000 |
Why?
|
Half-Life | 1 | 1987 | 661 | 0.000 |
Why?
|
Lymphocytes | 1 | 1994 | 2617 | 0.000 |
Why?
|
Environmental Exposure | 1 | 2001 | 4232 | 0.000 |
Why?
|
Phenotype | 1 | 2004 | 16367 | 0.000 |
Why?
|
Cell Cycle | 1 | 1994 | 2967 | 0.000 |
Why?
|
Artifacts | 1 | 1995 | 1904 | 0.000 |
Why?
|
Cytokines | 1 | 2001 | 7323 | 0.000 |
Why?
|
Antibody Specificity | 1 | 1987 | 1095 | 0.000 |
Why?
|
Polymethacrylic Acids | 1 | 1985 | 34 | 0.000 |
Why?
|
Swine | 1 | 1995 | 5918 | 0.000 |
Why?
|
Cross-Sectional Studies | 1 | 2005 | 25039 | 0.000 |
Why?
|
Interleukin-6 | 1 | 1994 | 3203 | 0.000 |
Why?
|
DNA Restriction Enzymes | 1 | 1983 | 570 | 0.000 |
Why?
|
Circadian Rhythm | 1 | 1995 | 2624 | 0.000 |
Why?
|
Surface Properties | 1 | 1985 | 1184 | 0.000 |
Why?
|
Mass Spectrometry | 1 | 1989 | 2204 | 0.000 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2005 | 11726 | 0.000 |
Why?
|
Patient Compliance | 1 | 1992 | 2684 | 0.000 |
Why?
|
Escherichia coli | 1 | 1994 | 4217 | 0.000 |
Why?
|
Endopeptidases | 1 | 1985 | 772 | 0.000 |
Why?
|
Liver Diseases | 1 | 1989 | 1253 | 0.000 |
Why?
|
Creatinine | 1 | 1985 | 1919 | 0.000 |
Why?
|
Infarction | 1 | 1981 | 244 | 0.000 |
Why?
|
Serine Endopeptidases | 1 | 1985 | 1073 | 0.000 |
Why?
|
Genes | 1 | 1983 | 1893 | 0.000 |
Why?
|
Liver | 1 | 1994 | 7475 | 0.000 |
Why?
|
Intermittent Claudication | 1 | 1981 | 309 | 0.000 |
Why?
|
Aorta, Abdominal | 1 | 1981 | 646 | 0.000 |
Why?
|
Reproducibility of Results | 1 | 1995 | 19905 | 0.000 |
Why?
|
Mice, Inbred C57BL | 1 | 1994 | 21833 | 0.000 |
Why?
|
Renal Dialysis | 1 | 1985 | 1783 | 0.000 |
Why?
|
Chromosome Mapping | 1 | 1983 | 4740 | 0.000 |
Why?
|
Kidney Failure, Chronic | 1 | 1985 | 2535 | 0.000 |
Why?
|
Mice | 1 | 1994 | 81201 | 0.000 |
Why?
|
Kidney | 1 | 1981 | 7184 | 0.000 |
Why?
|